FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Antibody and its antigen-binding fragment specifically binding human delta-like ligand 4 (DLL4) are presented, characterized by sequences determining sections complementarity (CDR). Besides, there are disclosed: isolated antibody coding nucleic acid under the invention or its antigen-binding fragment; expression vector and host cell; as well as, pharmaceutical composition and application of antibody or antigen-binding fragment according to the invention in preparing a drug for reducing human DLL4 activity in an individual human.
EFFECT: present invention can find further application in therapy of diseases associated with Notch signaling.
29 cl, 30 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC DLL4-BINDING PROTEINS | 2010 |
|
RU2570639C2 |
| INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
| IL-12/P40 BINDING PROTEINS | 2006 |
|
RU2461571C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
| ANTI-INTERFERON BETA ANTIBODIES AND THEIR USE | 2017 |
|
RU2750454C2 |
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| ANTIBODIES AGAINST IL-33, COMPOSITIONS, METHODS AND THEIR APPLICATION | 2017 |
|
RU2740309C2 |
